Health Care

Nektar Therapeutics (NASDAQ:NKTR) Takes Off in Trading Today - Up by 18.83%

Nektar Therapeutics (NASDAQ:NKTR) Takes Off in Trading Today - Up by 18.83%”

Mizuho Securities analyst Difei Yang assigned a Buy rating to Nektar Therapeutics (NASDAQ: NKTR) today. American International Group Inc. now owns 118,366 shares of the biopharmaceutical company's stock valued at $2,841,000 after purchasing an additional 6,476 shares during the last quarter. This represents an increase of Infinity compared to the average daily volume of 0 call options.

In other news, CAO Jillian B. Thomsen sold 2,648 shares of the company's stock in a transaction dated Wednesday, August 16th. Ashmore Group Plc sold 21,355 shares as the company's stock rose 11.75% with the market. Following the sale, the chief executive officer now owns 122,908 shares in the company, valued at $1,705,963.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. $33,255 worth of stock was sold by Doberstein Stephen K on Tuesday, May 16. The stock was sold at an average price of $13.88, for a total transaction of $1,297,197.04. The company realized a fall in short interest of -1.29% between September 29, 2017 and October 13, 2017.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its position in shares of Nektar Therapeutics by 0.6% during the second quarter.

Nektar Therapeutics has gapped open sharply higher Monday morning and is now up 8.38 at $40.88 on above average volume. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company's stock valued at $1,582,000 after acquiring an additional 800 shares during the last quarter.

Vanguard Gp holds 0.01% in Nektar Therapeutics (NASDAQ:NKTR) or 14.01 million shares. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company's stock worth $129,000 after purchasing an additional 535 shares during the period. It also increased its holding in Gran Tierra Energy Inc (NYSEMKT:GTE) by 345,800 shares in the quarter, for a total of 2.50M shares, and has risen its stake in Banco Macro Sa (NYSE:BMA). Institutional investors own 95.11% of the company's stock.

Equity Research firms now have a positive stance on shares of Nektar Therapeutics (NASDAQ:NKTR). Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $33.67. For the past month, Nektar Therapeutics's stock has been 41.18%, 68.57% for the last quarter, 64.06% for the past six months and 137.57% for the past 52 weeks. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.04. The business had revenue of $36.30 million for the quarter, compared to analysts' expectations of $32.42 million.

"In the dose-escalation stage of the PIVOT trial, we've observed important response rates across all three tumor types - melanoma, renal cell carcinoma and non-small lung cancer - in both PD-L1 positive and PD-L1 negative patients", said Mary Tagliaferri, M.D., Senior Vice President of Clinical Development at Nektar Therapeutics. The firm's revenue for the quarter was up 321.2% on a year-over-year basis. During the same period last year, the firm earned ($0.32) earnings per share. sell-side analysts predict that Nektar Therapeutics will post -0.83 earnings per share for the current year. Finally, Brean Capital reissued a "buy" rating and set a $23.00 price objective on shares of Nektar Therapeutics in a research note on Friday, September 30th. World Asset Management Inc boosted its stake in Nektar Therapeutics by 5.6% in the 2nd quarter. Finally, Canaccord Genuity assumed coverage on shares of Nektar Therapeutics in a report on Thursday. Following the acquisition, the director now directly owns 121,333 shares of the company's stock, valued at $1,637,995.50. Aegis Capital initiated Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, November 8 with "Buy" rating. Nektar Therapeutics has a consensus rating of "Buy" and an average target price of $28.64. Analysts' mean recommendation for the stock is 1.60 (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).

Among 2 analysts covering IRSA Inversiones (NYSE:IRS), 1 have Buy rating, 0 Sell and 1 Hold. The stock's price is 39.99 and their relative strength index (RSI) stands at 90.97.

WARNING: This story was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & worldwide copyright legislation.

Like this



13 November 2017
MPs Will Get Final Say On Brexit Deal, Government Agrees In U-Turn
But if they reject the deal the Government strikes with the EU, Britain will instead leave the bloc with no deal, he confirmed. Mr Davis said the talks were expected to move on to discussing a future free trade agreement "as soon as possible".

13 November 2017
Amitabh Bachchan: Marriages are wonderful
The Bachchans attended a family wedding recently, which means plenty of selfies and frame-worthy moments for the family album. Bachchan senior and Bachchan junior also opted for traditional sherwanis from the studios of their favourite designer duo.

13 November 2017
Analysts Ratings on: JetBlue Airways Corporation (JBLU)
The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. Equities research analysts anticipate that JetBlue Airways Corporation will post $1.75 EPS for the current year.

13 November 2017
Carbon monoxide poisoning sends 3 to hospital in Winnipeg
Responders were called to a house on Garfield Street North, where the home was determined to be a "polluted environment". The three occupants of the home were in stable condition, he said.

13 November 2017
Rally protesting Meek Mill's prison sentence to be held Monday
The rally is going down today in Philadelphia outside the Criminal Justice Center at 13th and Filbert Streets. Last week, Meek Mill was sentenced to two to four years in prison for violating his probation .

13 November 2017
House 'Committed' to Retaining Some State and Local Tax Deductions, Chairman Says
Eliminating some deductions hurts, for example, teachers who spend about $500 a year from their pockets to buy school supplies. Senate Republican leaders have said they want to hold a full Senate vote before Thanksgiving, which falls on November 23.

13 November 2017
Investors Buy Large Volume of Abercrombie & Fitch Put Options (NYSE:ANF)
It turned negative, as 38 investors sold Abercrombie & Fitch Co. shares while 56 reduced holdings. (NYSE: ANF ) for 20,030 shares. Nationwide Fund Advisors owned approximately 0.10% of Abercrombie & Fitch worth $888,000 as of its most recent SEC filing.

13 November 2017
Allegis Investment Advisors LLC Raises Stake in Wells Fargo & Company
Piper Jaffray Companies reiterated a "hold" rating on shares of Wells Fargo & in a research report on Sunday, July 30th. The Firm operates through four divisions: Agricultural Products, Pressurized Vessels, Modular Buildings and Tools.

13 November 2017
RPS Group plc (RPS) PT Raised to GBX 330 at Liberum Capital
In other news, insider Brian Gilvary purchased 70 shares of the business's stock in a transaction dated Monday, September 11th. The shares were acquired at an average price of GBX 446 ($5.87) per share, with a total value of £312.20 ($410.63).

13 November 2017
Eli Lilly and (NASDAQ:LLY ) Getting Somewhat Positive Press Coverage, Analysis Shows
It worsened, as 61 investors sold LLY shares while 400 reduced holdings. 72 funds opened positions while 128 raised stakes. Altfest L J & Company Inc decreased Aetna Inc New (NYSE:AET) stake by 6,816 shares to 6,316 valued at $959,000 in 2017Q2.